IP Library › Granted Patent US 10,383,897
Granted Patent B2
US 10,383,897 · App. 14/735,727 · Granted Aug 20, 2019

Placental stem cell populations

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,383,897
App. No.
14/735,727
Granted
Aug 20, 2019
Kind
B2
Abstract

The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.

Claims (38)

1. A pharmaceutical composition comprising a population of isolated adherent placental stem cells, dimethyl sulfoxide (DMSO), and albumin, wherein said placental stem cells:

express genes at a detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells (BM-MSCs); wherein said genes comprise ELOVL2, ST3GAL6, ST6GALNAC5, or SLC12A8; wherein at least 70% of said placental stem cells are non-maternal in origin; and

wherein said placental stem cells have been passaged between 3 and 10 times.

2. The pharmaceutical composition of claim 1 , wherein said population comprises from 10 6 to 10 7 placental stem cells.

3. The pharmaceutical composition of claim 1 , wherein said population comprises from 10 7 to 10 8 placental stem cells.

4. The pharmaceutical composition of claim 1 , wherein at least 90% of said placental stem cells are non-maternal in origin.

5. The pharmaceutical composition of claim 1 , wherein said genes further comprise CD200.

6. The pharmaceutical composition of claim 5 , wherein said genes further comprise ARTS-1, IER3, IL6, KRT18, LRAP, MEST, NFE2L3, or TGFB2.

7. The pharmaceutical composition of claim 1 , wherein said expression of said genes is detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells over 3 population doublings.

8. The pharmaceutical composition of claim 1 , wherein said expression of said genes is detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells over 11-14 population doublings.

9. The pharmaceutical composition of claim 1 , wherein said expression of said genes is detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells over 24-38 population doublings.

10. The pharmaceutical composition of claim 1 , wherein said population has undergone at least 5 population doublings.

11. The pharmaceutical composition of claim 10 , wherein said population has undergone between 15 and 30 population doublings.

12. The pharmaceutical composition of claim 10 , wherein said population has undergone about 20 population doublings.

13. The pharmaceutical composition of claim 1 , additionally comprising stem cells that are not obtained from placental tissue.

14. The pharmaceutical composition of claim 1 , wherein said placental stem cells have been cryopreserved.

15. The pharmaceutical composition of claim 1 , wherein said placental stem cells express said one or more genes at a detectably higher level than an equivalent number of BM-MSCs in medium comprising DMEM-LG and MCDB-201; 2% fetal calf serum, 1× insulin-transferrin-selenium, 1× lenolenic-acid-bovine-serum-albumin, 10 −9 M dexamethasone, 10 −4 M ascorbic acid 2-phosphate, 10 ng/ml epidermal growth factor, and 10 ng/ml platelet derived-growth factor.

16. The pharmaceutical composition of claim 1 , wherein said placental stem cells have the ability to replicate 10-40 times in culture.

17. The pharmaceutical composition of claim 1 , wherein said placental stem cells are isolated from a human postpartum placenta by digestion using trypsin, or are cultured from cells isolated from a human postpartum placenta by digestion using trypsin.

18. The pharmaceutical composition of claim 1 , wherein said placental stem cells have been separated from at least 90% of cells from the placenta from which the placental stem cells are isolated.

19. The pharmaceutical composition of claim 18 , wherein said placental stem cells have been separated from at least 95% of cells from the placenta from which the placental stem cells are isolated.

20. The pharmaceutical composition of claim 19 , wherein said placental stem cells have been separated from at least 99% of cells from the placenta from which the placental stem cells are isolated.

21. The pharmaceutical composition of claim 1 , wherein said placental stem cells have been passaged 6 times.

22. The pharmaceutical composition of claim 1 , wherein at least 90% of cells in the population are said placental stem cells.

23. The pharmaceutical composition of claim 1 , wherein at least 95% of cells in the population are said placental stem cells.

24. The pharmaceutical composition of claim 1 , wherein at least 99% of cells in the population are said placental stem cells.

25. The pharmaceutical composition of claim 1 , wherein said placental stem cells express said genes at at least a three-fold higher level than an equivalent number of BM-MSCs.

26. The pharmaceutical composition of claim 1 , wherein said genes expressed by said placental stem cells comprise ELOVL2, ST3GAL6, ST6GALNAC5, and SLC12A8.

27. The pharmaceutical composition of claim 26 , wherein said placental stem cells express said genes at a detectably higher level than an equivalent number of BM-MSCs in medium comprising DMEM-LG and MCDB-201; 2% fetal calf serum, 1× insulin-transferrin-selenium, 1× lenolenic-acid-bovine-serum-albumin, 10 −9 M dexamethasone, 10 −4 M ascorbic acid 2-phosphate, 10 ng/ml epidermal growth factor, and 10 ng/ml platelet derived-growth factor.

28. The pharmaceutical composition of claim 26 , wherein said population comprises from 10 6 to 10 7 placental stem cells.

29. The pharmaceutical composition of claim 26 , wherein said population comprises from 10 7 to 10 8 placental stem cells.

30. The pharmaceutical composition of claim 1 , wherein said genes comprise ELOVL2.

31. The pharmaceutical composition of claim 1 , wherein said genes comprise ST3GAL6.

32. The pharmaceutical composition of claim 1 , wherein said genes comprise ST6GALNAC5.

33. The pharmaceutical composition of claim 1 , wherein said genes comprise SLC12A8.

34. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is an injectable solution.

35. A method of treating ischemia in a subject in need thereof, comprising administering the pharmaceutical composition of claim 1 .

36. A method of treating inflammation in a subject in need thereof, comprising administering the pharmaceutical composition of claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2025
From: CELULARITY INC.
To: CELENIV PTE. LTD.
Reel/Frame 073705/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2017
From: CLARITY ACQUISITION II LLC
To: CELULARITY, INC.
Reel/Frame 044780/0261 →
MERGER Recorded Nov 8, 2017
From: ANTHROGENESIS CORPORATION
To: CLARITY ACQUISITION II LLC
Reel/Frame 044413/0680 →